Alto Neuroscience (NYSE:ANRO) Posts Earnings Results, Beats Expectations By $0.13 EPS

Alto Neuroscience (NYSE:ANRO) posted its quarterly earnings results on Tuesday. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.13, FiscalAI reports.

Alto Neuroscience Stock Performance

ANRO stock traded up $0.95 during midday trading on Tuesday, reaching $28.75. The company had a trading volume of 515,791 shares, compared to its average volume of 430,120. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average price of $26.84 and a 200 day moving average price of $24.37. Alto Neuroscience has a fifty-two week low of $10.80 and a fifty-two week high of $37.48. The firm has a market capitalization of $1.13 billion, a PE ratio of -11.88 and a beta of 1.42.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ANRO. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Tuesday, October 27th. BTIG Research lifted their price target on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Finally, Wedbush upped their price objective on Alto Neuroscience from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Thursday, August 13th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Alto Neuroscience has an average rating of “Moderate Buy” and a consensus price target of $37.88.

Insider Activity at Alto Neuroscience

In other Alto Neuroscience news, CFO Nicholas Smith sold 24,056 shares of the firm’s stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total value of $621,125.92. Following the sale, the chief financial officer owned 24,060 shares in the company, valued at approximately $621,229.20. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 11.25% of the company’s stock.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.